CN112111575A - 胰岛素样生长因子2在恶性肿瘤预后和治疗选择中的应用 - Google Patents
胰岛素样生长因子2在恶性肿瘤预后和治疗选择中的应用 Download PDFInfo
- Publication number
- CN112111575A CN112111575A CN202011004230.7A CN202011004230A CN112111575A CN 112111575 A CN112111575 A CN 112111575A CN 202011004230 A CN202011004230 A CN 202011004230A CN 112111575 A CN112111575 A CN 112111575A
- Authority
- CN
- China
- Prior art keywords
- cancer
- igf2
- immunotherapy
- inhibitor
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011004230.7A CN112111575B (zh) | 2020-09-22 | 2020-09-22 | 胰岛素样生长因子2在恶性肿瘤预后和治疗选择中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011004230.7A CN112111575B (zh) | 2020-09-22 | 2020-09-22 | 胰岛素样生长因子2在恶性肿瘤预后和治疗选择中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112111575A true CN112111575A (zh) | 2020-12-22 |
CN112111575B CN112111575B (zh) | 2023-01-10 |
Family
ID=73800956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011004230.7A Active CN112111575B (zh) | 2020-09-22 | 2020-09-22 | 胰岛素样生长因子2在恶性肿瘤预后和治疗选择中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112111575B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170107577A1 (en) * | 2014-03-11 | 2017-04-20 | The Council Of The Queensland Institute Of Medical Research | Determining Cancer Aggressiveness, Prognosis and Responsiveness to Treatment |
CN111148534A (zh) * | 2017-09-29 | 2020-05-12 | 勃林格殷格翰国际有限公司 | 抗igf和抗pd-1抗癌组合疗法 |
-
2020
- 2020-09-22 CN CN202011004230.7A patent/CN112111575B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170107577A1 (en) * | 2014-03-11 | 2017-04-20 | The Council Of The Queensland Institute Of Medical Research | Determining Cancer Aggressiveness, Prognosis and Responsiveness to Treatment |
CN111148534A (zh) * | 2017-09-29 | 2020-05-12 | 勃林格殷格翰国际有限公司 | 抗igf和抗pd-1抗癌组合疗法 |
Non-Patent Citations (2)
Title |
---|
陈慧娟等: "乳腺癌免疫治疗: 生物标志物、药物及疫苗", 《中国生物化学与分子生物学报》 * |
高伟: "IGF-Ⅱ在乳腺癌中的表达及其与细胞增殖的关系", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Also Published As
Publication number | Publication date |
---|---|
CN112111575B (zh) | 2023-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10273308B2 (en) | Methods of producing antibodies specific for p95 | |
DK2602623T3 (en) | METHOD OF DETECTING INTRACELLULAR TRUNCTED RECEPTORS | |
US9110064B2 (en) | Methods for diagnosis and treatment of endometrial cancer | |
Barresi et al. | Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density? | |
EP2213686A1 (en) | Tumor markers and methods of use thereof | |
Hsueh et al. | Expression pattern and prognostic significance of claudins 1, 4, and 7 in nasopharyngeal carcinoma | |
JP2014501387A (ja) | 抗ccl25および抗ccr9抗体を用いる癌の検出 | |
CN103502470A (zh) | 嗅介蛋白-4蛋白(olfm4)在结肠直肠癌诊断中的用途 | |
Fadia et al. | PD-L1 expression in papillary thyroid cancer with and without lymphocytic thyroiditis: a cross sectional study | |
AU2010274581B2 (en) | A method of diagnosing cancer | |
WO2013035095A1 (en) | Methods for diagnosing cancer | |
US20240069029A1 (en) | Pd-ecgf as biomarker of cancer | |
CN113677994A (zh) | 用于评估t细胞功能和预测对疗法的应答的方法和药剂 | |
CN112111575B (zh) | 胰岛素样生长因子2在恶性肿瘤预后和治疗选择中的应用 | |
KR102401657B1 (ko) | 동반진단용 암 조직 내 보체 c7 바이오마커 조성물 및 이의 용도 | |
JP7012363B2 (ja) | がん患者におけるfstl1阻害剤による治療効果を予測するためのバイオマーカー | |
KR20190058082A (ko) | 유방암의 진단 및 치료를 위한 바이오 마커 | |
US20210003574A1 (en) | Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment | |
JP7042753B2 (ja) | 免疫チェックポイント阻害剤の投与対象となる個体の選択方法 | |
JPWO2020101039A1 (ja) | 血中ケモカインを用いた免疫チェックポイント阻害薬の治療効果判定 | |
CN118028466A (zh) | Slc6a6基因在作为肿瘤标志物和肿瘤治疗靶点中的应用 | |
WO2014108707A1 (en) | Identification of patients for breast cancer theraphy using t128 family members as markers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Hongzhong Inventor after: Ren Guosheng Inventor after: Wu Yushen Inventor after: Li Qin Inventor after: Du Qi Inventor before: Ren Guosheng Inventor before: Li Hongzhong Inventor before: Wu Yushen Inventor before: Li Qin Inventor before: Du Qi |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20221213 Address after: 400010 No.1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing Applicant after: THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL University Address before: 20 / F, building a, building 5, First Affiliated Hospital of Chongqing Medical College, No.1 Youyi Road, Yuzhong District, Chongqing, 400010 Applicant before: Ren Guosheng Applicant before: Li Hongzhong |
|
GR01 | Patent grant | ||
GR01 | Patent grant |